SG11201502659YA - Stable, low viscosity antibody formulation - Google Patents
Stable, low viscosity antibody formulationInfo
- Publication number
- SG11201502659YA SG11201502659YA SG11201502659YA SG11201502659YA SG11201502659YA SG 11201502659Y A SG11201502659Y A SG 11201502659YA SG 11201502659Y A SG11201502659Y A SG 11201502659YA SG 11201502659Y A SG11201502659Y A SG 11201502659YA SG 11201502659Y A SG11201502659Y A SG 11201502659YA
- Authority
- SG
- Singapore
- Prior art keywords
- stable
- low viscosity
- antibody formulation
- viscosity antibody
- formulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718379P | 2012-10-25 | 2012-10-25 | |
| PCT/US2013/066313 WO2014066468A1 (en) | 2012-10-25 | 2013-10-23 | Stable, low viscosity antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201502659YA true SG11201502659YA (en) | 2015-05-28 |
Family
ID=50545202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502659YA SG11201502659YA (en) | 2012-10-25 | 2013-10-23 | Stable, low viscosity antibody formulation |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150239970A1 (en) |
| EP (1) | EP2911693A4 (en) |
| JP (1) | JP2015536934A (en) |
| KR (1) | KR20150070384A (en) |
| CN (2) | CN104768578A (en) |
| AU (1) | AU2013334740A1 (en) |
| BR (1) | BR112015008186A2 (en) |
| CA (1) | CA2885862A1 (en) |
| HK (2) | HK1211840A1 (en) |
| MX (1) | MX2015004668A (en) |
| RU (1) | RU2015119547A (en) |
| SG (1) | SG11201502659YA (en) |
| WO (1) | WO2014066468A1 (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201608703SA (en) | 2012-11-08 | 2016-12-29 | Eleven Biotherapeutics Inc | Il-6 antagonists and uses thereof |
| CA2910065C (en) * | 2013-05-15 | 2023-09-19 | Medimmune Limited | Purification of recombinantly produced polypeptides |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| TWI694836B (en) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | Antibody formulation |
| ES2572919T3 (en) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2600488T3 (en) | 2014-05-23 | 2017-02-09 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2756275T3 (en) | 2014-11-07 | 2020-04-27 | Sesen Bio Inc | Enhanced anti-IL-6 antibodies |
| EP3294273A4 (en) * | 2015-05-08 | 2018-12-05 | Incube Labs, LLC | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| JP2018529756A (en) * | 2015-07-31 | 2018-10-11 | メディミューン リミテッド | Methods for treating hepcidin-mediated disorders |
| EP3769781B1 (en) * | 2015-08-19 | 2023-04-19 | Astrazeneca AB | Stable anti-ifnar1 formulation |
| WO2017147293A1 (en) * | 2016-02-23 | 2017-08-31 | Eleven Biotherapeutics, Inc. | Il-6 antagonist formulations and uses thereof |
| EP3443346B1 (en) * | 2016-04-13 | 2023-08-30 | Medimmune, LLC | Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| DK3479819T3 (en) * | 2016-06-30 | 2024-04-15 | Celltrion Inc | STABLE LIQUID PHARMACEUTICAL PREPARATION |
| TWI656882B (en) * | 2016-08-10 | 2019-04-21 | 南韓商賽特瑞恩股份有限公司 | Stable liquid pharmaceutical formulation of anti-influenza virus antibody |
| CA3037440A1 (en) * | 2016-09-27 | 2018-04-05 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
| KR102617264B1 (en) | 2016-10-19 | 2023-12-29 | 인벤라 인코포레이티드 | antibody structure |
| BR112019011769A2 (en) * | 2016-12-16 | 2019-11-12 | Samsung Bioepis Co Ltd | stable aqueous anti-c5 antibody composition |
| EA201991204A1 (en) | 2016-12-22 | 2019-12-30 | Университа Дельи Студи Манья Греча Катандзаро | MONOCLONAL ANTIBODY AGAINST UNIQUE Sialoglycosylated Tumor-Associated Epitope CD43 |
| EP3576790A4 (en) | 2017-02-01 | 2020-12-23 | Yale University | Treatment of diuretic resistance |
| CA3054386A1 (en) * | 2017-03-01 | 2018-09-07 | Medimmune Limited | Formulations of monoclonal antibodies |
| US10646569B2 (en) | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| BR112020013519A2 (en) | 2018-01-05 | 2020-12-01 | Corvidia Therapeutics, Inc | method for treating an inflammation. |
| EP3802580A1 (en) | 2018-06-05 | 2021-04-14 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
| CN112543627A (en) | 2018-07-05 | 2021-03-23 | 拜耳公司 | Novel stable high concentration anti-FXIa antibody formulations |
| US20200061015A1 (en) * | 2018-08-23 | 2020-02-27 | Janssen Biotech, Inc. | Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations |
| MA55033A (en) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | THERAPEUTIC ANTIBODY FORMULATION |
| CN111686247B (en) * | 2019-03-13 | 2022-07-29 | 苏州康乃德生物医药有限公司 | Liquid compositions comprising antibodies to human interleukin-4 receptor alpha |
| EP3962942A1 (en) * | 2019-05-01 | 2022-03-09 | Novo Nordisk A/S | Anti-il-6 antibody formulation |
| CN112915201B (en) * | 2019-12-06 | 2023-06-27 | 珠海市丽珠单抗生物技术有限公司 | Liquid formulations comprising anti-IL-17 antibodies |
| WO2023169986A1 (en) * | 2022-03-07 | 2023-09-14 | Mabxience Research, S.L. | Stable formulations for antibodies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0403964B8 (en) * | 2003-04-04 | 2021-05-25 | Genentech Inc | stable liquid formulations, article of manufacture and use of these formulations for the treatment of ige-mediated dysfunction |
| JO3058B1 (en) * | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | Anti-IL-6 Antibodies,Compositions,Methods and uses |
| DK1960430T3 (en) * | 2005-12-09 | 2015-01-05 | Ucb Pharma Sa | ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR HUMANT IL-6 |
| WO2007074880A1 (en) * | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing stabilizing preparation |
| TW200831528A (en) * | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| PE20091174A1 (en) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT |
| TWI440469B (en) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| KR20110108398A (en) * | 2009-01-29 | 2011-10-05 | 메디뮨 엘엘씨 | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
| JO3417B1 (en) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |
| NZ609557A (en) * | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
-
2013
- 2013-10-23 KR KR1020157013150A patent/KR20150070384A/en not_active Application Discontinuation
- 2013-10-23 RU RU2015119547A patent/RU2015119547A/en not_active Application Discontinuation
- 2013-10-23 MX MX2015004668A patent/MX2015004668A/en unknown
- 2013-10-23 CN CN201380055029.3A patent/CN104768578A/en active Pending
- 2013-10-23 US US14/437,585 patent/US20150239970A1/en not_active Abandoned
- 2013-10-23 CA CA2885862A patent/CA2885862A1/en not_active Abandoned
- 2013-10-23 CN CN201610854508.7A patent/CN106421782A/en not_active Withdrawn
- 2013-10-23 WO PCT/US2013/066313 patent/WO2014066468A1/en active Application Filing
- 2013-10-23 JP JP2015539744A patent/JP2015536934A/en active Pending
- 2013-10-23 AU AU2013334740A patent/AU2013334740A1/en not_active Abandoned
- 2013-10-23 BR BR112015008186A patent/BR112015008186A2/en not_active IP Right Cessation
- 2013-10-23 EP EP13848584.2A patent/EP2911693A4/en not_active Withdrawn
- 2013-10-23 SG SG11201502659YA patent/SG11201502659YA/en unknown
-
2015
- 2015-12-24 HK HK15112690.1A patent/HK1211840A1/en unknown
-
2016
- 2016-03-01 HK HK16102332.5A patent/HK1214499A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1214499A1 (en) | 2016-07-29 |
| AU2013334740A1 (en) | 2015-04-02 |
| BR112015008186A2 (en) | 2017-09-19 |
| WO2014066468A1 (en) | 2014-05-01 |
| EP2911693A1 (en) | 2015-09-02 |
| EP2911693A4 (en) | 2016-04-27 |
| CN104768578A (en) | 2015-07-08 |
| RU2015119547A (en) | 2016-12-20 |
| AU2013334740A8 (en) | 2015-04-09 |
| JP2015536934A (en) | 2015-12-24 |
| US20150239970A1 (en) | 2015-08-27 |
| CN106421782A (en) | 2017-02-22 |
| HK1211840A1 (en) | 2016-06-03 |
| CA2885862A1 (en) | 2014-05-01 |
| KR20150070384A (en) | 2015-06-24 |
| WO2014066468A8 (en) | 2015-04-09 |
| MX2015004668A (en) | 2015-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1214499A1 (en) | Stable, low viscosity antibody formulation | |
| HK1203146A1 (en) | Antibody formulation | |
| IL237625A0 (en) | Anti-mcam antibodies, compositions comprising same and uses thereof | |
| HK1221900A1 (en) | Stable, aqueous antibody formulations | |
| SI3117837T1 (en) | Antibody formulations | |
| BR112014028602A2 (en) | liquid formulation. | |
| IL235004A0 (en) | Anti-fgfr2 antibodies, compositions comprising same and uses thereof | |
| ZA201408955B (en) | Anti-blys antibody | |
| HK1199844A1 (en) | Il-17 antibody formulation il-17 | |
| HK1202445A1 (en) | New formulation | |
| ZA201306000B (en) | Stable formulation | |
| EP2881431A4 (en) | Viscous composition | |
| AU2012905439A0 (en) | Formulation | |
| AU2012905410A0 (en) | Formulation | |
| AU2012902062A0 (en) | Liquid Formulation |